Clinical trial

Assessing the Efficacy of Four Drug Combinations as the Next First-line Therapy…

NCT00164710 · Centers for Disease Control and Prevention, U.S. Fed · Completed

Key facts

NCT number NCT00164710
Title Assessing the Efficacy of Four Drug Combinations as the Next First-line Therapy for Uncomplicated Malaria in Malawi
Official title An Open Randomised Trial of the Efficacy of Sulfadoxine-Pyrimethamine (SP), Amodiaquine + SP (AQ-SP), AQ + Artesunate (AQ-Art), Chlorproguanil-Dapsone + Art (CD-Art), and Lumefantrine-Artemether (LA) for Uncomplicated Malaria in Malawi
Lead sponsor Centers for Disease Control and Prevention, U.S. Fed
Collaborators Ministry of Health and Population, Malawi
Status Completed
Phase Phase 4
Study type Interventional
Conditions Malaria, Falciparum
Intervention type Drug
Interventions sulfadoxine-pyrimethamine, amodiaquine plus sulfadoxine-pyrimethamine, amodiaquine plus artesunate, chlorproguanil-dapsone plus artesunate, lumefantrine-artemether
Enrollment 365
Start date Apr 1, 2005
Primary completion Sep 1, 2005
Completion Sep 1, 2005
First posted Sep 14, 2005
Last update posted Sep 27, 2012
Countries Malawi

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies